Top news of the week: 23.06.2020.
#biotech #biopharma #COVID19 #GeneTherapy #microbiome
Startups
In recent years the #biopharma industry has become one of the most critical to the MA economy. As the industry works to continue operations & ensure safety for lab & non-lab workers, many co's are implementing their own #COVID19 testing procedures https://t.co/0kX6t08sUs
OpenFor some biotech employees in the age of COVID-19, the workday starts at the bathroom sink
Tango Therapeutics in Cambridge tests workers' gargled samples, then e-mails the results later that day.
RT @maggieotoole: Nice to wake up & see @labcentral's very own @JFruehauf & Celina Chang quoted in today's @WSJ article "Biotech Startups Look to Test Employees for Covid-19 in Bid to Get Back to Normal" https://t.co/DaL9e82h7P PS Celina don't you think it's about time you signed up for @Twitter?
OpenBiotech Startups Look to Test Employees for Covid-19 in Bid to Get Back to Normal
Biotechnology startups are seeking to test employees for Covid-19 and taking other precautions to protect laboratory workers as they move to resume more normal operations.
RT @RebeccaDRobbins: Had a great conversation with @tshakac about genetics, the field's diversity problem, and what should be done to address it.
Listen to the interview (https://t.co/Sjtp3NoaxU) or read a transcript (https://t.co/pxGjYsuPAh).
OpenListen: The latest on treating Covid-19, vaccine politics, and diversifying genetics
In this episode, we talk to geneticist Tshaka Cunningham about the deep racial inequities in the field of genomics and what can be done to correct them.
Timing Is an Essential Element of Cell & Gene Therapy Product Development
- by @sarahdc
https://t.co/Zhx6Mrei33
$FOLD
OpenTiming Is an Essential Element of Cell & Gene Therapy Product Development
The science underpinning the latest investigational cell and gene therapies is complex enough. But the rapid advance of technologies that support
The new fund is Epidarex’s third since it set up shop in 2010. Its ethos has always been to find innovation outside of biotech hot spots, but this is the first fund the firm has closed since creating its discovery engine, Epidarex Exeed. https://t.co/iAVayycHIv
OpenTransatlantic Epidarex banks $126M to back U.K. biotech startups
Epidarex Capital raised £102.1 million ($126 million) in its third fund. It will bankroll life sciences companies from “emerging hubs” across the U.K., investing £2 million to £5 million at ...
RT @nathanvardi: Billionaire Pablo Legorreta’s Big Royalty Pharma IPO Soars via @forbes https://t.co/Mbya1bsZvE
OpenBillionaire Pablo Legorreta’s Big Royalty Pharma IPO Soars
One of Wall Street's most successful private equity investors takes his pool of pharmaceutical royalties public.
In big year for #microbiome drugs, a small #biotech sets the bar https://t.co/bG83p1YfzR by @realJacobBell
OpenIn big year for microbiome drugs, a small biotech sets the bar
Data from Finch Therapeutics will likely be held up against two rivals planning to present their own clinical results later this year.
“We believe the FDA will likely approve at least one vaccine prior to the November election,” said Jefferies health-care strategist Jared Holz, who said he's basing his prediction, in part, on signals from vaccine-development companies. https://t.co/t5v1gOOqmL
OpenOpinion: Here’s why the FDA may approve a Covid-19 vaccine before the November elections, according to Jefferies’ biotech-research team
If true, any approval may not actually benefit a vaccine company, but instead other parts of the stock market.